Comparative study on the diagnostic value of multiparametric transrectal ultrasound and multiparametric MRI in prostate cancer
10.3760/cma.j.issn.1000-6702.2020.01.004
- VernacularTitle: 经直肠多模态超声与多模态MRI检查对前列腺癌诊断价值的对照研究
- Author:
Yingying LI
1
;
Mingbo ZHANG
1
;
Fan WU
1
;
Jun ZHANG
2
;
Yukun LUO
1
Author Information
1. Department of Ultrasound, First Medical Center of PLA General Hospital, Beijing 100853, China
2. Department of Radiology, First Medical Center of PLA General Hospital, Beijing 100853, China
- Publication Type:Clinical Trail
- Keywords:
Prostatic neoplasms;
Prostate cancer;
Magnetic resonance imaging;
Transrectal ultrasound;
Multiparametric
- From:
Chinese Journal of Urology
2020;41(1):19-25
- CountryChina
- Language:Chinese
-
Abstract:
Objective:The aim of the study is to compare the diagnostic value of multiparametric transrectal ultrasound(TRUS) and multiparametric magnetic resonance imaging (MRI) in prostate cancer.
Methods:The clinical data of 102 patients who received multiparametric TRUS (including conventional transrectal ultrasound, shear wave sonoelastography and contrast enhanced ultrasound), multiparametric MRI(including T2 weighted diffusion weighted, and dynamic contrast enhanced MRI) and laboratory tests from April 2016 to May 2018 were retrospectively analyzed. The average age was 66.1 years old, ranging 38.0-85.0 years old. The average PSA was 30.1 ng/ml, ranging 0.4-227.0 ng/ml. The average PSAD was 0.67 ng/ml2, ranging 0.02-4.27 ng/ml2. The pathology results from TRUS guided biopsy or surgical operation were chosen as gold standard. Diagnostic performance including sensitivity, specificity, positive predictive value(PPV), negative predictive value(NPV), accuracy and area under the receiver operating characteristic curve(AUROC)of multiparametric TRUS and multiparametric MRI in prostate cancer were analyzed.
Results:There were 62 prostate cancer and 40 BPH patients in our study. Parallel multiparametric TRUS diagnosed 63 prostate cancer and 39 BPH, and multiparametric MRI diagnosed 75 prostate cancer and 27 BPH. The sensitivity, specificity and accuracy of parallel multiparametric TRUS were 98.4%, 70.0% and 87.3%, respectively. And those of multiparametric MRI were 95.2%, 60.0% and 81.4%, respectively. The AUROC of parallel multiparametric TRUS and multiparametric MRI were 0.842 and 0.776, with no significant differences(P=0.208).
Conclusion:The diagnostic value of multiparametric TRUS was not inferior to multiparametric MRI in prostate cancer.
